Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder
This study is investigating how suvorexant (SUVO), a medication, affects sleep, stress, and drug cravings in people who are in early recovery from stimulant use disorder (cocaine or methamphetamine). Researchers also want to see if SUVO impacts how long participants stay in a residential treatment program and their completion rates. You might be able to join if you are between 18 and 65 years old, speak English, and have a stimulant use disorder. The study aims to measure changes in your total sleep duration and how often you wake up after falling asleep, both tracked by a watch. It will also assess your self-reported sleep quality. The current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 20 participants. It compares the effects of suvorexant (SUVO) to standard care (TAU).
- What's involved
- Participants will receive SUVO for 7 days, taken in the evening before bed, from Day 5 through Day 11. Sleep will be assessed using an actigraphy watch and self-reported questionnaires at various points between Day 4 and Day 12.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will assess residential program length of stay and completion rates for 13-30 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Heather Webber, PhD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center, Houston
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in total sleep duration as assessed by the actigraphy watchBaseline (Day 4), Day 5, day 6, day 7, day 8, day 9, day 10, day 11
- Change in wake after sleep onset measured via actigraphy watchBaseline (Day 4), Day 5, day 6, day 7, day 8, day 9, day 10, day 11
- Change in self reported sleep quality as assessed by the Insomnia Severity Index (ISI)Day 5 and Day 12
This is a 7 item questionnaire and is rated on a five-point Likert scale ('0' representing none or not at all and '4' representing very much). Total scores range from 0 to 28, with higher combined scores indicating worse insomnia severity.
- Changes in self reported sleep disturbance as assessed by the Patient Reported Outcomes Measurement Information System Short Form (PROMIS-SF)Day 5 and Day 12
This is a 4 item questionnaire and each is scored from 1-5 for a score range of 4-20, higher number indicating worse outcome
- Changes in self reported Sleep-Related Impairment as assessed by the Patient Reported Outcomes Measurement Information System Short Form (PROMIS-SF)Day 5 and Day 12
This is an 8 item questionnaire and each is scored from 1-5 for a total score range of 8-40, higher number indicating worse outcome
- Change in self-reported stress as assessed by the Visual Analog Scale (VAS)Day 5 and Day 12
This is measured from 0=no stress, 10=extreme stress
- Change in stress and anxiety as assessed by the Depression, Anxiety and Stress Scale (DASS)Day 5 and Day 12
The DASS 21 is a 21 item self report questionnaire. Each item is scored from 0 (did not apply to me at all over the last week) to 3 (applied to me very much or most of the time over the past week), higher score indicating a worse outcome
- Change in craving as assessed by the self reported Stimulant Craving Questionnaire (STCQ)Day 5 and Day 12
This is a 10 item questionnaire, each is scored from 0 (strongly disagree) to 6 (strongly agree) for a total score range of 0-60, higher score indicating worse outcome